Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Clinical Pharmacology Advances and ApplicationsOpen Access

Metabolomics Insights into the Benefits of SGLT2 Inhibitors in Type 2 Diabetes

View Full Paper
Ask AI
Bookmark
Share

Authors

AKArtemis KyriakidouTKTheocharis KoufakisHGHelen Gika

Discussion

Loading...

Member takes

Overview

Narrative review summarizes metabolomic evidence in type 2 diabetes, indicating SGLT2 inhibitors enhance metabolic adaptation and offer cardiorenal protection.

Key Points

  • SGLT2 inhibitors induce a metabolic shift from glucose utilization to ketone bodies and fatty acids.
  • Key metabolite changes involve increases in ketone bodies and alterations in branched-chain amino acids.
  • Metabolomic adaptations are linked to cardiovascular and renal protective effects associated with SGLT2 inhibitors.
  • Further longitudinal studies are crucial to establish the clinical significance of these metabolic adaptations.

Cite This Study

Kyriakidou et al. (2025) studied this question.

synapsesocial.com/papers/68c1dda254b1d3bfb60fc809https://doi.org/10.2147/cpaa.s497906
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: From Metabolic Mechanisms to International Guidelines2026 · 1 citations
  2. 2SGLT2 Inhibitors: Multifaceted Therapeutic Agents in Cardiometabolic and Renal Diseases2025 · 16 citations
  3. 3Sodium-Glucose Cotransporter-2 Inhibitors in Diabetes and Beyond: Mechanisms, Pleiotropic Benefits, and Clinical Use—Reviewing Protective Effects Exceeding Glycemic Control2025 · 19 citations
  4. 4Pleiotropic effects of SGLT2 inhibitors beyond diabetes2026
  5. 5SGLT2 inhibitors: Beyond glycemic control2024 · 58 citations